Ernexa Therapeutics Inc. Contract with Customer, Performance Obligation Satisfied in Previous Period
Ernexa Therapeutics Inc. (ERNA) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2025-03-12
- Ernexa Therapeutics Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-12-31 was $0.00.
- Ernexa Therapeutics Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-09-30 was $0.00.
- Ernexa Therapeutics Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-06-30 was $0.00.
- Ernexa Therapeutics Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-03-31 was $0.00.
- Ernexa Therapeutics Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $0.00.
- Ernexa Therapeutics Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $0.00.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $0.00 derived: sum of 2 quarters · filed 2025-03-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-12 | $0.00 10-K · filed 2025-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2024-08-13 | $0.00 derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | $0.00 derived: sum of 3 quarters · filed 2024-05-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |